Search results
Results from the WOW.Com Content Network
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...
Surgical removal of the prostate, or prostatectomy, is a common treatment either for early-stage prostate cancer or for cancer that has failed to respond to radiation therapy. The most common type is radical retropubic prostatectomy , when the surgeon removes the prostate through an abdominal incision.
On Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients. The ...
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
Sep. 27—Logansport Memorial Hospital is home to modern prostate cancer treatments that are rarely seen in the United States. The treatments, MRI Fusion Biopsy and High Intensity Focused ...
Two weeks ago, Dendreon Corp. (DNDN) reported that its experimental prostate cancer treatment, the therapeutic vaccine Provenge, was significantly successful in prolonging patient survival, but ...
LDR prostate brachytherapy (seed or line source implantation) is a proven treatment for low to high risk localized prostate cancer (when the cancer is contained within the prostate). [ 4 ] [ 5 ] Under a general anaesthetic, the radioactive seeds are injected through fine needles directly into the prostate , so that the radiotherapy can destroy ...
After treatment with white button mushroom extract in mice and patients with prostate cancer, scientists discovered a decline in the amount of immune-suppressing cells in tumors.